Globus Medical, Inc.
GMEDHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeGlobus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. With a market capitalization of $10.08B, it sits in large-cap territory. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives.
Market Cap
$10.08B
Beta
0.96
P/E (TTM)
19.19
P/E (Fwd)
13.90
EPS (TTM)
$3.91
EPS (Fwd)
$5.40
ROE
11.8%
ROA
8.7%
Cash
$595.1M
Total Debt
$111.9M
Free CF
$554.2M
52W Change
34.0%
Annual Financials
Cash vs Debt
Where GMED stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, GMED finished 3.04% below its 150-day moving average ($85.13) and 4.06% below its 200-day moving average ($86.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GMED overbought or oversold?
At the August 28, 2026 close, GMED's RSI(14) was 50.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $595.1M in cash comfortably exceeding the $111.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $554.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 11.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.02B (2022) to $2.94B (2025), reflecting a 187% increase over the period.
With cash comfortably exceeding debt, GMED has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Globus Medical, Inc. and its sector.